Validating a screening agar for linezolid-resistant enterococci

Abstract Background Linezolid is an alternative treatment option for infections with multidrug-resistant Gram-positive bacteria including vancomycin-resistant enterococci. Some countries report an increasing number of isolates with resistance to linezolid. The recent publication of the Commission fo...

Full description

Bibliographic Details
Main Authors: Guido Werner, Carola Fleige, Ingo Klare, Robert E. Weber, Jennifer K. Bender
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-019-4711-y
id doaj-c019acf1350b4a3f83617c5239ecec07
record_format Article
spelling doaj-c019acf1350b4a3f83617c5239ecec072020-12-27T12:03:38ZengBMCBMC Infectious Diseases1471-23342019-12-011911510.1186/s12879-019-4711-yValidating a screening agar for linezolid-resistant enterococciGuido Werner0Carola Fleige1Ingo Klare2Robert E. Weber3Jennifer K. Bender4Division Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci (NRC), Robert Koch Institute, Wernigerode BranchDivision Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci (NRC), Robert Koch Institute, Wernigerode BranchDivision Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci (NRC), Robert Koch Institute, Wernigerode BranchDivision Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci (NRC), Robert Koch Institute, Wernigerode BranchDivision Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, National Reference Centre for Staphylococci and Enterococci (NRC), Robert Koch Institute, Wernigerode BranchAbstract Background Linezolid is an alternative treatment option for infections with multidrug-resistant Gram-positive bacteria including vancomycin-resistant enterococci. Some countries report an increasing number of isolates with resistance to linezolid. The recent publication of the Commission for Hospital Hygiene in Germany on enterococci/VRE recommends screening for linezolid-resistant enterococci (LRE). However, a suitable selective medium or a genetic test is not available. Our aim was to establish a selective screening agar for LRE detection and validate its application with a comprehensive collection of clinical LRE and linezolid-susceptible enterococci. Methods We decided to combine the selective power of an enterococcal screening agar with a supplementation of linezolid. Several rounds of analyses with reference, control and test strains and under varying linezolid concentrations of a wider and a smaller range were investigated and assessed. The collection of linezolid-resistant enterococcal control strains included isolates with different resistance mechanisms (23S rDNA mutations, cfr(B), optrA, poxtA). Finally, we validated our LRE screening agar with 400 samples sent to our National Reference Centre in 2019. Results Several rounds of pre-tests and confirmatory analyses favored Enterococcosel® Agar supplemented with a concentration of 2 mg/L linezolid. A 48 h incubation period was essential for accurate identification of LRE strains. Performance of the LRE screening agar revealed a sensitivity of 96.6% and a specificity of 94.4%. Conclusions Here we describe preparation of a suitable screening agar and a procedure to identify LRE isolates with high accuracy.https://doi.org/10.1186/s12879-019-4711-ycfr(B)optrApoxtALinezolid resistance
collection DOAJ
language English
format Article
sources DOAJ
author Guido Werner
Carola Fleige
Ingo Klare
Robert E. Weber
Jennifer K. Bender
spellingShingle Guido Werner
Carola Fleige
Ingo Klare
Robert E. Weber
Jennifer K. Bender
Validating a screening agar for linezolid-resistant enterococci
BMC Infectious Diseases
cfr(B)
optrA
poxtA
Linezolid resistance
author_facet Guido Werner
Carola Fleige
Ingo Klare
Robert E. Weber
Jennifer K. Bender
author_sort Guido Werner
title Validating a screening agar for linezolid-resistant enterococci
title_short Validating a screening agar for linezolid-resistant enterococci
title_full Validating a screening agar for linezolid-resistant enterococci
title_fullStr Validating a screening agar for linezolid-resistant enterococci
title_full_unstemmed Validating a screening agar for linezolid-resistant enterococci
title_sort validating a screening agar for linezolid-resistant enterococci
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2019-12-01
description Abstract Background Linezolid is an alternative treatment option for infections with multidrug-resistant Gram-positive bacteria including vancomycin-resistant enterococci. Some countries report an increasing number of isolates with resistance to linezolid. The recent publication of the Commission for Hospital Hygiene in Germany on enterococci/VRE recommends screening for linezolid-resistant enterococci (LRE). However, a suitable selective medium or a genetic test is not available. Our aim was to establish a selective screening agar for LRE detection and validate its application with a comprehensive collection of clinical LRE and linezolid-susceptible enterococci. Methods We decided to combine the selective power of an enterococcal screening agar with a supplementation of linezolid. Several rounds of analyses with reference, control and test strains and under varying linezolid concentrations of a wider and a smaller range were investigated and assessed. The collection of linezolid-resistant enterococcal control strains included isolates with different resistance mechanisms (23S rDNA mutations, cfr(B), optrA, poxtA). Finally, we validated our LRE screening agar with 400 samples sent to our National Reference Centre in 2019. Results Several rounds of pre-tests and confirmatory analyses favored Enterococcosel® Agar supplemented with a concentration of 2 mg/L linezolid. A 48 h incubation period was essential for accurate identification of LRE strains. Performance of the LRE screening agar revealed a sensitivity of 96.6% and a specificity of 94.4%. Conclusions Here we describe preparation of a suitable screening agar and a procedure to identify LRE isolates with high accuracy.
topic cfr(B)
optrA
poxtA
Linezolid resistance
url https://doi.org/10.1186/s12879-019-4711-y
work_keys_str_mv AT guidowerner validatingascreeningagarforlinezolidresistantenterococci
AT carolafleige validatingascreeningagarforlinezolidresistantenterococci
AT ingoklare validatingascreeningagarforlinezolidresistantenterococci
AT roberteweber validatingascreeningagarforlinezolidresistantenterococci
AT jenniferkbender validatingascreeningagarforlinezolidresistantenterococci
_version_ 1724369529396527104